Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
Status:
Completed
Trial end date:
2021-02-16
Target enrollment:
Participant gender:
Summary
This study, is a Phase I/II clinical trial in three parts: Phase I Dose Escalation, Phase II,
Part 1 RPTD Cohort, and Phase II, Part 2 Expansion. The first two parts have been completed.
The Phase II, Part 2 Expansion will assess if treatment with rigosertib in combination with
azacitidine, has measurable effects in patients with myelodysplastic syndrome (MDS). Safety
of patients is an objective throughout all parts of the study.